FITC Anti-DR4 antibody [DR-4-02] (ab59047)
Key features and details
- FITC Mouse monoclonal [DR-4-02] to DR4
- Suitable for: IP, Functional Studies, Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
FITC Anti-DR4 antibody [DR-4-02]
See all DR4 primary antibodies -
Description
FITC Mouse monoclonal [DR-4-02] to DR4 -
Host species
Mouse -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
The antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines. -
Tested applications
Suitable for: IP, Functional Studies, Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Fusion protein (Human) containing the extracellular part of DR4 and the constant part of the heavy chain of human IgG1.
-
General notes
Do not use after expiration date stamped on vial label. Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.4
Preservative: 0.097% Sodium azide
Constituent: 0.2% BSA
0.2% high grade protease free BSA -
Concentration information loading...
-
Purity
Size exclusion -
Purification notes
The antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography). -
Primary antibody notes
Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells. -
Clonality
Monoclonal -
Clone number
DR-4-02 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab59047 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent concentration.
|
|
Functional Studies |
Use at an assay dependent concentration.
in cultivation medium. Final concentration of TRAIL: 20-200 ng/ml. Note: It is recommended that the antibody is added 15 min before the addition of TRAIL. |
|
Flow Cyt |
Use at an assay dependent concentration.
ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
Notes |
---|
IP
Use at an assay dependent concentration. |
Functional Studies
Use at an assay dependent concentration. in cultivation medium. Final concentration of TRAIL: 20-200 ng/ml. Note: It is recommended that the antibody is added 15 min before the addition of TRAIL. |
Flow Cyt
Use at an assay dependent concentration. ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
Target
-
Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. -
Tissue specificity
Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells. -
Sequence similarities
Contains 1 death domain.
Contains 3 TNFR-Cys repeats. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8797 Human
- Omim: 603611 Human
- SwissProt: O00220 Human
- Unigene: 213467 Human
- Unigene: 591834 Human
-
Alternative names
- Apo2 antibody
- CD261 antibody
- Cytotoxic TRAIL receptor antibody
see all
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab59047 has been referenced in 4 publications.
- Strekalova E et al. Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction. Methods Mol Biol 1866:61-73 (2019). PubMed: 30725408
- Piggott L et al. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clin Cancer Res 24:2452-2463 (2018). PubMed: 29363524
- Nesterenko I et al. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One 7:e49219 (2012). Flow Cyt ; Human . PubMed: 23145127
- Fan S et al. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 21:10-24 (2010). IP . PubMed: 19823077